How Cleveland Diagnostics Is Redefining Prostate Cancer Testing

In this episode of Diagnosing Dx, I’m joined by Arnon Chait, PhD, MBA, Chief Innovation Officer at Cleveland Diagnostics.Arnon shares his journey from NASA physicist to diagnostics innovator, and explains how Cleveland Diagnostics tackled one of the biggest challenges in prostate cancer testing: turning a widely used but flawed marker like PSA into something more clinically useful. We explore the role of protein structure and biomarkers in disease, why so many diagnostics fall short after the science is proven, and what it means to build from real clinical need rather than lab-first thinking.We also discuss the road from development to commercialization, the realities of regulatory strategy and FDA approval, and where diagnostics could be heading next as AI and new technologies reshape disease detection. This is a practical conversation about what it really takes to make diagnostics work in the real world.Key takeaways:🔹 Why strong science alone is not enough to build a successful diagnostic🔹 How Cleveland Diagnostics rethought prostate cancer testing beyond traditional PSA🔹 Why clinical utility, adoption, and reimbursement matter as much as validation🔹 What Arnon learned moving from physics and space science into diagnostics🔹 How AI and new technologies could shape the future of disease detectionGuest:Arnon Chait, PhD, MBAChief Innovation Officer, Cleveland DiagnosticsLinkedIn: https://www.linkedin.com/in/arnonchait/ Host:David FilbyFounder & CEO, Elevra ConsultingLinkedIn: https://www.linkedin.com/in/davidfilby/Chapters:00:00 Introduction and background03:56 Transition from NASA to diagnostics06:48 Lessons from NASA applied to diagnostics09:40 Founding Cleveland Diagnostics and developing the prostate cancer test15:52 Clinical challenges in prostate cancer18:31 Commercialization and FDA approval21:53 Future of Cleveland Diagnostics and the impact of AI27:22 Market outlook, industry changes, and lessons learned🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.#Diagnostics #ProstateCancer #Biotech #Biomarkers #Proteomics #PrecisionMedicine #MedicalDiagnostics #HealthcareInnovation #DiseaseDetection #MolecularDiagnostics #ClinicalUtility #AIinHealthcare #CancerDiagnostics #LifeSciences #DiagnosingDx